Literature DB >> 19360306

The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells.

Chirlei Büneker1, Andrea Mohr, Ralf Michael Zwacka.   

Abstract

The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in many cancer cells. However, a significant proportion of tumours are TRAIL-resistant erecting a major hurdle for a successful TRAIL-based treatment regimen in the future. In this context, it would be a major advantage to be able to identify the tumours that respond to TRAIL. The existence of two apoptosis-inducing receptors (TRAIL-R1 and TRAIL-R2) and two receptors that cannot transmit an apoptotic signal and have an inhibitory function (TRAIL-R3 and TRAIL-R4) make TRAIL signalling complicated. We analysed the surface expression of all four membrane-bound TRAIL receptors in cancer cell lines of various origin and primary cancer and normal cells and found a good correlation between TRAIL-sensitivity and the expression of TRAIL-R1 alone, but an even better correlation when a ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4 was analysed. Experimental overexpression of TRAIL-R1 alone or in combination with TRAIL-R4 in PANC-1 cells confirmed our correlation results. Similar to the surface expression-apoptosis correlation analysis we found a high correlation between TRAIL-sensitivity and the mRNA level ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4. A value of <0.85 for the ratio predicted TRAIL resistance in both protein and RNA analysis. Hence, TRAIL receptor RNA expression analysis by real-time PCR might be a feasible approach to predict possible TRAIL-responses in individual tumour samples.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360306     DOI: 10.3892/or_00000353

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Authors:  Carmella Romeo; Matthew C Weber; Mahsa Zarei; Danielle DeCicco; Saswati N Chand; Angie D Lobo; Jordan M Winter; Janet A Sawicki; Jonathan N Sachs; Nicole Meisner-Kober; Charles J Yeo; Rajanikanth Vadigepalli; Mark L Tykocinski; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2016-04-06       Impact factor: 5.852

Review 2.  Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer.

Authors:  Kelly Xue Jing Jong; Elsa Haniffah Mejia Mohamed; Zaridatul Aini Ibrahim
Journal:  Apoptosis       Date:  2022-10-07       Impact factor: 5.561

Review 3.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

4.  Adipose-derived stem cell-released osteoprotegerin protects cardiomyocytes from reactive oxygen species-induced cell death.

Authors:  Jiyun Lee; Seahyung Lee; Chang Youn Lee; Hyang-Hee Seo; Sunhye Shin; Jung-Won Choi; Sang Woo Kim; Jong-Chul Park; Soyeon Lim; Ki-Chul Hwang
Journal:  Stem Cell Res Ther       Date:  2017-09-19       Impact factor: 6.832

5.  Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.

Authors:  R Yu; L Deedigan; S M Albarenque; A Mohr; R M Zwacka
Journal:  Cell Death Dis       Date:  2013-02-21       Impact factor: 8.469

6.  The enigmatic roles of caspases in tumor development.

Authors:  Richard Jäger; Ralf M Zwacka
Journal:  Cancers (Basel)       Date:  2010-11-24       Impact factor: 6.639

7.  Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.

Authors:  Neila Chekkat; Caterina M Lombardo; Cendrine Seguin; Marie-Charlotte Lechner; Florent Dufour; Yves Nominé; Marcella De Giorgi; Benoit Frisch; Olivier Micheau; Gilles Guichard; Danièle Altschuh; Sylvie Fournel
Journal:  Oncotarget       Date:  2018-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.